A Phase I Pharmacodynamic Study of GTI-2040, an Antisense Oligonucleotide Against Ribonuclotide Reductase, in Acute Leukemias: A California Cancer Consortium Study

We performed a phase I study of GTI-2040, an antisense oligonucleotide against ribonucleotide reductase mRNA, on a novel dosing schedule of days 1-4 and 15-18 by continuous infusion to examine efficacy and tolerability in patients with leukemia. A dose of 11 mg/kg/d was safely reached. Dose limiting...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Leuk Lymphoma
Main Authors: Kirschbaum, Mark H., Frankel, Paul, Synold, Timothy W., Xie, Zhiliang, Yen, Yun, Popplewell, Leslie, Chen, Robert, Aljitawi, Omar S., Tuscano, Joseph M., Chan, Kenneth K., Newman, Edward M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4969190/
https://ncbi.nlm.nih.gov/pubmed/26895565
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2016.1146947
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados